MET receptor tyrosine kinase inhibitor-containing pharmaceutical composition and application thereof
The invention discloses a pharmaceutical composition containing an MET receptor tyrosine kinase inhibitor and application. Specifically, a pharmaceutical combination comprising (i) an MET receptor tyrosine kinase inhibitor 6-(1-methyl-1H-pyrazol-4-yl)-1-((6-(1-methyl-1H-pyrazol-4-yl) imidazole [1, 2...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ZHANG YIXIANG LI YUE SUN DUANHONG LI LEPING WU QIUXIA ZHOU JUN ZHU MIAO QIAN SHEN |
| description | The invention discloses a pharmaceutical composition containing an MET receptor tyrosine kinase inhibitor and application. Specifically, a pharmaceutical combination comprising (i) an MET receptor tyrosine kinase inhibitor 6-(1-methyl-1H-pyrazol-4-yl)-1-((6-(1-methyl-1H-pyrazol-4-yl) imidazole [1, 2-a] pyridine-3-yl) sulfonyl)-1H-pyrazoline [4, 3-b] pyridine or a pharmaceutically acceptable salt thereof, and an EGFR mutant inhibitor or a pharmaceutically acceptable salt thereof. A method and use for treating or preventing cancer using said combination. The combination has beneficial therapeutic properties such as synergistic interaction, strong anti-proliferative activity in vitro or in vivo and/or strong anti-tumor response in vitro or in vivo, making it particularly suitable for the treatment of cancer.
一种含MET受体酪氨酸激酶抑制剂的药物组合物及应用。具体地，一种药物组合，其包含(i)MET受体酪氨酸激酶抑制剂6-(1-甲基-1H-吡唑-4-基)-1-((6-(1-甲基-1H-吡唑-4-基)咪唑[1，2-a]吡啶-3基)磺酰基)-1H-吡唑啉[4，3-b]吡啶或其药学上可接受的盐，以及EGFR突变体抑制剂或其药学上可接受的盐。一种使用所述组合来治疗或预防癌症的方法和用途。所述组合具有有益的治疗特性，如协同相 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN118159538A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN118159538A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN118159538A3</originalsourceid><addsrcrecordid>eNqNjDEOgkAQRWksjHqH8QAUhJBgaQjGRit6Mi6DTIDZye5YeHs3xgNY_fy89_82G25tB4EcqfkA9g4-shDMLBgJWCZ-cCK582LIwvIEnTCs6Ohl7HAB51dNI2MvgDIAqi4JfLtNFMiP-2wz4hLp8Mtddry0XXPNSX1PUdOZkPXNvSjqojpVZX0u_3E-cAZACQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MET receptor tyrosine kinase inhibitor-containing pharmaceutical composition and application thereof</title><source>esp@cenet</source><creator>ZHANG YIXIANG ; LI YUE ; SUN DUANHONG ; LI LEPING ; WU QIUXIA ; ZHOU JUN ; ZHU MIAO ; QIAN SHEN</creator><creatorcontrib>ZHANG YIXIANG ; LI YUE ; SUN DUANHONG ; LI LEPING ; WU QIUXIA ; ZHOU JUN ; ZHU MIAO ; QIAN SHEN</creatorcontrib><description>The invention discloses a pharmaceutical composition containing an MET receptor tyrosine kinase inhibitor and application. Specifically, a pharmaceutical combination comprising (i) an MET receptor tyrosine kinase inhibitor 6-(1-methyl-1H-pyrazol-4-yl)-1-((6-(1-methyl-1H-pyrazol-4-yl) imidazole [1, 2-a] pyridine-3-yl) sulfonyl)-1H-pyrazoline [4, 3-b] pyridine or a pharmaceutically acceptable salt thereof, and an EGFR mutant inhibitor or a pharmaceutically acceptable salt thereof. A method and use for treating or preventing cancer using said combination. The combination has beneficial therapeutic properties such as synergistic interaction, strong anti-proliferative activity in vitro or in vivo and/or strong anti-tumor response in vitro or in vivo, making it particularly suitable for the treatment of cancer.
一种含MET受体酪氨酸激酶抑制剂的药物组合物及应用。具体地，一种药物组合，其包含(i)MET受体酪氨酸激酶抑制剂6-(1-甲基-1H-吡唑-4-基)-1-((6-(1-甲基-1H-吡唑-4-基)咪唑[1，2-a]吡啶-3基)磺酰基)-1H-吡唑啉[4，3-b]吡啶或其药学上可接受的盐，以及EGFR突变体抑制剂或其药学上可接受的盐。一种使用所述组合来治疗或预防癌症的方法和用途。所述组合具有有益的治疗特性，如协同相</description><language>chi ; eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240607&DB=EPODOC&CC=CN&NR=118159538A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76419</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240607&DB=EPODOC&CC=CN&NR=118159538A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHANG YIXIANG</creatorcontrib><creatorcontrib>LI YUE</creatorcontrib><creatorcontrib>SUN DUANHONG</creatorcontrib><creatorcontrib>LI LEPING</creatorcontrib><creatorcontrib>WU QIUXIA</creatorcontrib><creatorcontrib>ZHOU JUN</creatorcontrib><creatorcontrib>ZHU MIAO</creatorcontrib><creatorcontrib>QIAN SHEN</creatorcontrib><title>MET receptor tyrosine kinase inhibitor-containing pharmaceutical composition and application thereof</title><description>The invention discloses a pharmaceutical composition containing an MET receptor tyrosine kinase inhibitor and application. Specifically, a pharmaceutical combination comprising (i) an MET receptor tyrosine kinase inhibitor 6-(1-methyl-1H-pyrazol-4-yl)-1-((6-(1-methyl-1H-pyrazol-4-yl) imidazole [1, 2-a] pyridine-3-yl) sulfonyl)-1H-pyrazoline [4, 3-b] pyridine or a pharmaceutically acceptable salt thereof, and an EGFR mutant inhibitor or a pharmaceutically acceptable salt thereof. A method and use for treating or preventing cancer using said combination. The combination has beneficial therapeutic properties such as synergistic interaction, strong anti-proliferative activity in vitro or in vivo and/or strong anti-tumor response in vitro or in vivo, making it particularly suitable for the treatment of cancer.
一种含MET受体酪氨酸激酶抑制剂的药物组合物及应用。具体地，一种药物组合，其包含(i)MET受体酪氨酸激酶抑制剂6-(1-甲基-1H-吡唑-4-基)-1-((6-(1-甲基-1H-吡唑-4-基)咪唑[1，2-a]吡啶-3基)磺酰基)-1H-吡唑啉[4，3-b]吡啶或其药学上可接受的盐，以及EGFR突变体抑制剂或其药学上可接受的盐。一种使用所述组合来治疗或预防癌症的方法和用途。所述组合具有有益的治疗特性，如协同相</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjDEOgkAQRWksjHqH8QAUhJBgaQjGRit6Mi6DTIDZye5YeHs3xgNY_fy89_82G25tB4EcqfkA9g4-shDMLBgJWCZ-cCK582LIwvIEnTCs6Ohl7HAB51dNI2MvgDIAqi4JfLtNFMiP-2wz4hLp8Mtddry0XXPNSX1PUdOZkPXNvSjqojpVZX0u_3E-cAZACQ</recordid><startdate>20240607</startdate><enddate>20240607</enddate><creator>ZHANG YIXIANG</creator><creator>LI YUE</creator><creator>SUN DUANHONG</creator><creator>LI LEPING</creator><creator>WU QIUXIA</creator><creator>ZHOU JUN</creator><creator>ZHU MIAO</creator><creator>QIAN SHEN</creator><scope>EVB</scope></search><sort><creationdate>20240607</creationdate><title>MET receptor tyrosine kinase inhibitor-containing pharmaceutical composition and application thereof</title><author>ZHANG YIXIANG ; LI YUE ; SUN DUANHONG ; LI LEPING ; WU QIUXIA ; ZHOU JUN ; ZHU MIAO ; QIAN SHEN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN118159538A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHANG YIXIANG</creatorcontrib><creatorcontrib>LI YUE</creatorcontrib><creatorcontrib>SUN DUANHONG</creatorcontrib><creatorcontrib>LI LEPING</creatorcontrib><creatorcontrib>WU QIUXIA</creatorcontrib><creatorcontrib>ZHOU JUN</creatorcontrib><creatorcontrib>ZHU MIAO</creatorcontrib><creatorcontrib>QIAN SHEN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHANG YIXIANG</au><au>LI YUE</au><au>SUN DUANHONG</au><au>LI LEPING</au><au>WU QIUXIA</au><au>ZHOU JUN</au><au>ZHU MIAO</au><au>QIAN SHEN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MET receptor tyrosine kinase inhibitor-containing pharmaceutical composition and application thereof</title><date>2024-06-07</date><risdate>2024</risdate><abstract>The invention discloses a pharmaceutical composition containing an MET receptor tyrosine kinase inhibitor and application. Specifically, a pharmaceutical combination comprising (i) an MET receptor tyrosine kinase inhibitor 6-(1-methyl-1H-pyrazol-4-yl)-1-((6-(1-methyl-1H-pyrazol-4-yl) imidazole [1, 2-a] pyridine-3-yl) sulfonyl)-1H-pyrazoline [4, 3-b] pyridine or a pharmaceutically acceptable salt thereof, and an EGFR mutant inhibitor or a pharmaceutically acceptable salt thereof. A method and use for treating or preventing cancer using said combination. The combination has beneficial therapeutic properties such as synergistic interaction, strong anti-proliferative activity in vitro or in vivo and/or strong anti-tumor response in vitro or in vivo, making it particularly suitable for the treatment of cancer.
一种含MET受体酪氨酸激酶抑制剂的药物组合物及应用。具体地，一种药物组合，其包含(i)MET受体酪氨酸激酶抑制剂6-(1-甲基-1H-吡唑-4-基)-1-((6-(1-甲基-1H-吡唑-4-基)咪唑[1，2-a]吡啶-3基)磺酰基)-1H-吡唑啉[4，3-b]吡啶或其药学上可接受的盐，以及EGFR突变体抑制剂或其药学上可接受的盐。一种使用所述组合来治疗或预防癌症的方法和用途。所述组合具有有益的治疗特性，如协同相</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN118159538A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | MET receptor tyrosine kinase inhibitor-containing pharmaceutical composition and application thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A50%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHANG%20YIXIANG&rft.date=2024-06-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN118159538A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |